Skip to main content

Articles

Page 31 of 60

  1. Coronary artery calcified plaque (CAC) is strongly predictive of cardiovascular disease (CVD) events and mortality, both in general populations and individuals with type 2 diabetes at high risk for CVD. CAC is...

    Authors: Laura M. Raffield, Amanda J. Cox, Michael H. Criqui, Fang-Chi Hsu, James G. Terry, Jianzhao Xu, Barry I. Freedman, J. Jeffrey Carr and Donald W. Bowden
    Citation: Cardiovascular Diabetology 2018 17:67
  2. Cardiovascular (CV) disease due to atherosclerosis is a major cause of morbidity and mortality in adult patients with diabetes, either type 1 or type 2 diabetes. The aim of the study was to assess the associat...

    Authors: Marc Carbonell, Esmeralda Castelblanco, Xavier Valldeperas, Àngels Betriu, Alícia Traveset, Minerva Granado-Casas, Marta Hernández, Federico Vázquez, Mariona Martín, Esther Rubinat, Albert Lecube, Josep Franch-Nadal, Elvira Fernández, Manel Puig-Domingo, Angelo Avogaro, Núria Alonso…
    Citation: Cardiovascular Diabetology 2018 17:66
  3. Type 2 diabetes is associated with endothelial dysfunction leading to cardiovascular disease. CD34+ endothelial Progenitor Cells (EPCs) are responsible for endothelial repair and neo-angiogenesis and can be us...

    Authors: Fiona J. Dore, Cleyton C. Domingues, Neeki Ahmadi, Nabanita Kundu, Yana Kropotova, Sara Houston, Carol Rouphael, Aytan Mammadova, Linda Witkin, Anamil Khiyami, Richard L. Amdur and Sabyasachi Sen
    Citation: Cardiovascular Diabetology 2018 17:65
  4. Exercise training is considered a cornerstone in the management of type 2 diabetes, which is associated with impaired endothelial function. However, the association of exercise training with endothelial functi...

    Authors: Shanhu Qiu, Xue Cai, Han Yin, Zilin Sun, Martina Zügel, Jürgen Michael Steinacker and Uwe Schumann
    Citation: Cardiovascular Diabetology 2018 17:64
  5. Cardiovascular disease (CVD) is a leading cause of death among adults with type 2 diabetes mellitus (T2D). We recently reported that glycemic control in patients with T2D can be significantly improved through ...

    Authors: Nasir H. Bhanpuri, Sarah J. Hallberg, Paul T. Williams, Amy L. McKenzie, Kevin D. Ballard, Wayne W. Campbell, James P. McCarter, Stephen D. Phinney and Jeff S. Volek
    Citation: Cardiovascular Diabetology 2018 17:56
  6. The aim of the present study was to evaluate the prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in patients with ST-segment elevation myocardial infarction (STEMI).

    Authors: Germán Cediel, Ferran Rueda, Claus Oxvig, Teresa Oliveras, Carlos Labata, Oriol de Diego, Marc Ferrer, M. Cruz Aranda-Nevado, Judith Serra-Gregori, Julio Núñez, Cosme García and Antoni Bayes-Genis
    Citation: Cardiovascular Diabetology 2018 17:63
  7. Type 2 diabetes (T2D) is associated with generalized vascular dysfunction characterized by increases in large artery stiffness, endothelial dysfunction, and vascular smooth muscle dysfunction. Sodium glucose c...

    Authors: Dustin M. Lee, Micah L. Battson, Dillon K. Jarrell, Shuofei Hou, Kayl E. Ecton, Tiffany L. Weir and Christopher L. Gentile
    Citation: Cardiovascular Diabetology 2018 17:62
  8. Patients with type 1 diabetes are more at risk of coronary artery disease than the general population. Although evidence points to a genetic risk there have been no study investigating genetic risk factors of ...

    Authors: Romain Charmet, Seamus Duffy, Sareh Keshavarzi, Beata Gyorgy, Michel Marre, Peter Rossing, Amy Jayne McKnight, Alexander P. Maxwell, Tarun veer Singh Ahluwalia, Andrew D. Paterson, David-Alexandre Trégouët and Samy Hadjadj
    Citation: Cardiovascular Diabetology 2018 17:61
  9. Multiple population based analyses have demonstrated a high incidence of cardiovascular disease (CVD) and cardiovascular (CV) mortality in subjects with T2DM that reduces life expectancy by as much as 15 years...

    Authors: Annayya R. Aroor, Camila Manrique-Acevedo and Vincent G. DeMarco
    Citation: Cardiovascular Diabetology 2018 17:59
  10. Type 2 diabetes mellitus (T2D) is associated with the development of left ventricular systolic dysfunction (LVSD) and heart failure with reduced ejection fraction (HFrEF). T2D patients with LVSD are at higher ...

    Authors: Selma Bouthoorn, Aisha Gohar, Gideon Valstar, Hester M. den Ruijter, J. B. Reitsma, Arno W. Hoes and Frans H. Rutten
    Citation: Cardiovascular Diabetology 2018 17:58
  11. Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be accounted for by conventional cardiov...

    Authors: W. David Strain and P. M. Paldánius
    Citation: Cardiovascular Diabetology 2018 17:57

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:120

  12. Sarcopenic obesity, defined as reduced skeletal muscle mass and power with increased adiposity, was reported to be associated with cardiovascular disease risks in previous cross-sectional studies. Whole body d...

    Authors: Tatsuya Fukuda, Ryotaro Bouchi, Takato Takeuchi, Kazutaka Tsujimoto, Isao Minami, Takanobu Yoshimoto and Yoshihiro Ogawa
    Citation: Cardiovascular Diabetology 2018 17:55
  13. To evaluate real-world patient characteristics, medication use, and health care utilization patterns in patients with type 2 diabetes with established cardiovascular disease (CVD).

    Authors: Kevin M. Pantalone, Anita D. Misra-Hebert, Todd M. Hobbs, Xinge Ji, Sheldon X. Kong, Alex Milinovich, Wayne Weng, Janine Bauman, Rahul Ganguly, Bartolome Burguera, Michael W. Kattan and Robert S. Zimmerman
    Citation: Cardiovascular Diabetology 2018 17:54
  14. It has been suggested that liraglutide could have an impact on glucose and lipid metabolism disorder and adhesion molecule activation, which may play important roles in the vascular damage of diabetes. In this...

    Authors: Xiao-min Chen, Wen-qiang Zhang, Yuan Tian, Li-fen Wang, Chan-chan Chen and Chuan-mei Qiu
    Citation: Cardiovascular Diabetology 2018 17:53
  15. Cardiovascular protection following empagliflozin therapy is not entirely attributable to the glucose lowering effect. Increased hematocrit might influence the shear stress that is the main force acting on the...

    Authors: Concetta Irace, Francesco Casciaro, Faustina Barbara Scavelli, Rosa Oliverio, Antonio Cutruzzolà, Claudio Cortese and Agostino Gnasso
    Citation: Cardiovascular Diabetology 2018 17:52
  16. The effect of change in blood glucose levels on the risk of cardiovascular disease among individuals without diabetes is currently unclear. We aimed to examine the association of change in fasting serum glucos...

    Authors: Gyeongsil Lee, Sung Min Kim, Seulggie Choi, Kyuwoong Kim, Su-Min Jeong, Joung Sik Son, Jae-Moon Yun and Sang Min Park
    Citation: Cardiovascular Diabetology 2018 17:51
  17. The urinary proteomic classifier CKD273 has shown promise for prediction of progressive diabetic nephropathy (DN). Whether it is also a determinant of mortality and cardiovascular disease in patients with micr...

    Authors: Gemma E. Currie, Bernt Johan von Scholten, Sheon Mary, Jose-Luis Flores Guerrero, Morten Lindhardt, Henrik Reinhard, Peter K. Jacobsen, William Mullen, Hans-Henrik Parving, Harald Mischak, Peter Rossing and Christian Delles
    Citation: Cardiovascular Diabetology 2018 17:50
  18. The author found errors in Table 1 after publication of the original article [1].

    Authors: Núria Alonso, Alicia Traveset, Esther Rubinat, Emilio Ortega, Nuria Alcubierre, Jordi Sanahuja, Marta Hernández, Angels Betriu, Carmen Jurjo, Elvira Fernández and Didac Mauricio
    Citation: Cardiovascular Diabetology 2018 17:49

    The original article was published in Cardiovascular Diabetology 2015 14:33

  19. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of cholesterol homeostasis, is associated with glucose metabolism. Liraglutide, a glucagon-like peptide-1 receptor agonist, can increase...

    Authors: Sheng-Hua Yang, Rui-Xia Xu, Chuan-Jue Cui, Yin Wang, Ying Du, Zhi-Guo Chen, Yu-Hong Yao, Chun-Yan Ma, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Jing Sun, Bu-Xing Chen and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2018 17:48
  20. Diabetic complications may be associated with impaired time-dependent glycemic control. Therefore, long-term glycemic variability, assessed by variations in haemoglobin A1c (HbA1c), may be a potential risk fac...

    Authors: Jian-bin Su, Li-hua Zhao, Xiu-lin Zhang, Hong-li Cai, Hai-yan Huang, Feng Xu, Tong Chen and Xue-qin Wang
    Citation: Cardiovascular Diabetology 2018 17:47
  21. In the last decade, several studies have reported an unexpected and seemingly paradoxical inverse correlation between BMI and incidence of cardiovascular diseases. This so called “obesity paradox effect” has b...

    Authors: Valentina Rovella, Lucia Anemona, Marina Cardellini, Manuel Scimeca, Andrea Saggini, Giuseppe Santeusanio, Elena Bonanno, Manuela Montanaro, Iacopo Maria Legramante, Arnaldo Ippoliti, Nicola Di Daniele, Massimo Federici and Alessandro Mauriello
    Citation: Cardiovascular Diabetology 2018 17:46
  22. Vascular calcifications are associated with a three- to fourfold increased risk of cardiovascular disease (CVD) and are highly prevalent in type 2 diabetes patients. Emerging evidence indicates that vascular c...

    Authors: Sabine R. Zwakenberg, Yvonne T. van der Schouw, Casper G. Schalkwijk, Annemieke M. W. Spijkerman and Joline W. J. Beulens
    Citation: Cardiovascular Diabetology 2018 17:45
  23. The reasons for reduced exercise capacity in diabetes mellitus (DM) remains incompletely understood, although diastolic dysfunction and diabetic cardiomyopathy are often favored explanations. However, there is...

    Authors: Timothy J. Roberts, Andrew T. Burns, Richard J. MacIsaac, Andrew I. MacIsaac, David L. Prior and André La Gerche
    Citation: Cardiovascular Diabetology 2018 17:44
  24. The authors found errors in Table 1 after publication of the original article [1].

    Authors: Iren D. Hjellestad, Marianne C. Astor, Roy M. Nilsen, Eirik Søfteland and Torbjørn Jonung
    Citation: Cardiovascular Diabetology 2018 17:42

    The original article was published in Cardiovascular Diabetology 2013 12:79

  25. The triglyceride glucose (TyG) index has been suggested as a simple surrogate marker of insulin resistance. However, there are limited data regarding the association between the TyG index and arterial stiffnes...

    Authors: Sang Bae Lee, Chul Woo Ahn, Byoung Kwon Lee, Shinae Kang, Ji Sun Nam, Ji Hong You, Min Jin Kim, Min Kyung Kim and Jong Suk Park
    Citation: Cardiovascular Diabetology 2018 17:41
  26. Determination of the impact of visceral obesity and epicardial adipose tissue thickness on stimulating growth factor levels during hospitalization for myocardial infarction is of potential importance for predi...

    Authors: Olga Gruzdeva, Evgenya Uchasova, Yulia Dyleva, Daria Borodkina, Olga Akbasheva, Ekaterina Belik, Viktoria Karetnikova, Natalia Brel, Alexander Kokov, Vasiliy Kashtalap and Olga Barbarash
    Citation: Cardiovascular Diabetology 2018 17:40
  27. Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® tria...

    Authors: Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Maximilian von Eynatten…
    Citation: Cardiovascular Diabetology 2018 17:39
  28. Following publication of the original article [1] the authors reported that the first affiliation (“Medical Center of the Graduate School, Nanchang University, China”) had been added in error, and that the cor...

    Authors: Honghong Zou, Baoqin Zhou and Gaosi Xu
    Citation: Cardiovascular Diabetology 2018 17:38

    The original article was published in Cardiovascular Diabetology 2017 16:65

  29. It is presently unclear whether glycemic variability (GV) is associated with baroreflex sensitivity (BRS), which is an early indicator of cardiovascular autonomic neuropathy. The present study is the first to ...

    Authors: Daisuke Matsutani, Masaya Sakamoto, Hiroyuki Iuchi, Souichirou Minato, Hirofumi Suzuki, Yosuke Kayama, Norihiko Takeda, Ryuzo Horiuchi and Kazunori Utsunomiya
    Citation: Cardiovascular Diabetology 2018 17:36
  30. We aimed to investigate in patients with type 2 diabetes whether aortic stiffness is: (i) associated with glycaemic control, (ii) associated with adverse outcomes and (iii) can be reversed on treatment with RA...

    Authors: Peter P. Swoboda, Bara Erhayiem, Rachel Kan, Adam K. McDiarmid, Pankaj Garg, Tarique A. Musa, Laura E. Dobson, Klaus K. Witte, Mark T. Kearney, Julian H. Barth, Ramzi Ajjan, John P. Greenwood and Sven Plein
    Citation: Cardiovascular Diabetology 2018 17:35
  31. Diabetes mellitus is characterized by chronic vascular disorder and presents a main risk factor for cardiovascular mortality. In particular, hyperglycaemia and inflammatory cytokines induce vascular circulatin...

    Authors: Marco Witkowski, Termeh Tabaraie, Daniel Steffens, Julian Friebel, Andrea Dörner, Carsten Skurk, Mario Witkowski, Bernd Stratmann, Diethelm Tschoepe, Ulf Landmesser and Ursula Rauch
    Citation: Cardiovascular Diabetology 2018 17:34
  32. Long-term visit-to-visit glycemic variability is an additional measure of glycemic control. We aimed to evaluate the prognostic value of several measures of glycemic variability for the occurrence of micro- an...

    Authors: C. R. L. Cardoso, N. C. Leite, C. B. M. Moram and G. F. Salles
    Citation: Cardiovascular Diabetology 2018 17:33
  33. Clinical complications associated with atherosclerotic plaques arise from luminal obstruction due to plaque growth or destabilization leading to rupture. We previously demonstrated that overexpression of insul...

    Authors: Nuria Beneit, José Luis Martín-Ventura, Carlota Rubio-Longás, Óscar Escribano, Gema García-Gómez, Silvia Fernández, Giorgio Sesti, Marta Letizia Hribal, Jesús Egido, Almudena Gómez-Hernández and Manuel Benito
    Citation: Cardiovascular Diabetology 2018 17:31
  34. The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26–27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of re...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa Lalic, Katarina Lalic, Jan Skrha, Paul Valensi and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2018 17:30
  35. There are inconsistent data about the role of serum phospholipid fatty acid composition in patients with type 2 diabetes (T2DM) and atherosclerotic cardiovascular disease (ASCVD). The aim of the study was to i...

    Authors: Malgorzata Poreba, Pawel Rostoff, Aleksander Siniarski, Magdalena Mostowik, Renata Golebiowska-Wiatrak, Jadwiga Nessler, Anetta Undas and Grzegorz Gajos
    Citation: Cardiovascular Diabetology 2018 17:29
  36. No study evaluated vascular health markers in subjects with non-alcoholic fatty liver disease (NAFLD) through a combined analysis of reactive hyperemia peripheral arterial tonometry (RH-PAT) and arterial stiff...

    Authors: Antonino Tuttolomondo, Salvatore Petta, Alessandra Casuccio, Carlo Maida, Vittoriano Della Corte, Mario Daidone, Domenico Di Raimondo, Rosaria Pecoraro, Roberto Fonte, Anna Cirrincione, Rita Zafonte, Daniela Cabibi, Calogero Cammà, Vito Di Marco, Anna Licata, Franco Magliozzo…
    Citation: Cardiovascular Diabetology 2018 17:28
  37. To examine the intensity of glycemic and blood pressure control in British adults with diabetes mellitus and whether control levels or treatment deintensification rates differ across health states.

    Authors: Finlay A. McAlister, Brendan Cord Lethebe, Caitlin Lambe, Tyler Williamson and Mark Lowerison
    Citation: Cardiovascular Diabetology 2018 17:27
  38. The extent of coronary collateral formation is a primary determinant of the severity of myocardial damage and mortality after coronary artery occlusion. Type 2 diabetes mellitus (T2DM) represents an important ...

    Authors: Ying Shen, Feng Hua Ding, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Lin Lu and Wei Feng Shen
    Citation: Cardiovascular Diabetology 2018 17:26
  39. Coronary artery disease often progresses more rapidly in diabetics, but the integrated impact of diabetes and early revascularization status on late or repeat revascularization in the contemporary era is less ...

    Authors: Ady Orbach, David A. Halon, Ronen Jaffe, Ronen Rubinshtein, Basheer Karkabi, Moshe Y. Flugelman and Barak Zafrir
    Citation: Cardiovascular Diabetology 2018 17:25
  40. Ultrasonic gray-scale median (GSM) of the carotid wall reflects its composition and low-GSM carotid plaque is considered to be vulnerable. This study aimed to evaluate the effect of sitagliptin, a dipeptidyl p...

    Authors: Naoto Katakami, Tomoya Mita, Yoko Irie, Mitsuyoshi Takahara, Taka-aki Matsuoka, Masahiko Gosho, Hirotaka Watada and Iichiro Shimomura
    Citation: Cardiovascular Diabetology 2018 17:24
  41. Skeletal muscle mass was negatively associated with metabolic syndrome prevalence in previous cross-sectional studies. The aim of this study was to investigate the impact of baseline skeletal muscle mass and c...

    Authors: Gyuri Kim, Seung-Eun Lee, Ji Eun Jun, You-Bin Lee, Jiyeon Ahn, Ji Cheol Bae, Sang-Man Jin, Kyu Yeon Hur, Jae Hwan Jee, Moon-Kyu Lee and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2018 17:23
  42. Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and...

    Authors: Bahira Shahim, Viveca Gyberg, Dirk De Bacquer, Kornelia Kotseva, Guy De Backer, Oliver Schnell, Jaakko Tuomilehto, David Wood and Lars Rydén
    Citation: Cardiovascular Diabetology 2018 17:21
  43. Metformin is the standard first-line drug for patients with Type 2 diabetes (T2DM). However, the optimal second-line oral anti-diabetic agent (ADA) remains unclear. We investigated the cardiovascular risk of v...

    Authors: Cheng-Wei Chan, Chu-Leng Yu, Jiunn-Cherng Lin, Yu-Cheng Hsieh, Che-Chen Lin, Chen-Ying Hung, Cheng-Hung Li, Ying-Chieh Liao, Chu-Pin Lo, Jin-Long Huang, Ching-Heng Lin and Tsu-Juey Wu
    Citation: Cardiovascular Diabetology 2018 17:20
  44. Depression is a prevalent, independent predictor of mortality in patients with heart failure (HF). Depression is also common in type 2 diabetes mellitus (T2DM), which is itself an important risk factor for HF....

    Authors: Ying Wang, Hong Yang, Mark Nolan, John Burgess, Kazuaki Negishi and Thomas H. Marwick
    Citation: Cardiovascular Diabetology 2018 17:19
  45. Patients with type-2 diabetes mellitus (T2DM) are at high risk of cardiovascular events, accentuated in the presence of hypertension. At present, it is unclear to what extent the guidelines for the management ...

    Authors: Roland E. Schmieder, Diethelm Tschöpe, Cornelia Koch, Taoufik Ouarrak and Anselm K. Gitt
    Citation: Cardiovascular Diabetology 2018 17:18
  46. The severity of the metabolic syndrome (MetS) is significantly associated with future coronary heart disease (CHD) among individuals without baseline Type 2 diabetes. However, the validity of assessing MetS se...

    Authors: Matthew J. Gurka, Yi Guo, Stephanie L. Filipp and Mark D. DeBoer
    Citation: Cardiovascular Diabetology 2018 17:17

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions